CAPR vs PTCT
CAPR: A clinical-stage biotechnology company developing novel cell and exosome-based therapies for Duchenne muscular dystrophy and other rare diseases. PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases.
Side-by-side fundamentals
| Metric | CAPR | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.01 | $62.56 | |
| Market cap | $466M | $5.2B | |
| Net margin FY2025, SEC XBRL | n/a | +39.4% | |
| Operating margin FY2025, SEC XBRL | n/a | +50.1% | |
| ROE FY2025, SEC XBRL | -34.4% | n/a | |
| ROA FY2025, SEC XBRL | -29.5% | +23.5% | PTCT higher |
| Debt / equity as of 2026-09-03 | 0.02 | 848.93 | CAPR lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -42.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.10 | 0.93 | |
| 1-year return as of 2026-10-08 close | +7.1% | -3.0% | CAPR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.